Britain snubs GSK in favour of US pharma giant for RSV vaccine

The NHS has turned to US drugs giant Pfizer over its British rival GSK for vaccines against Respiratory Syncytial Virus (RSV), the winter infection known as the “silent killer” of the elderly. Officials have signed a two-year supply agreement with Pfizer for more than 3.5 million doses of its RSV vaccine for older people and more than 1.4 million doses of the jab for pregnant mothers. It comes after the vaccine, which is among the first to treat the deadly …